A detailed landscape of genomic alterations in malignant peripheral nerve sheath tumor cell lines challenges the current MPNST diagnosis
Miriam Magallón‐LorenziD, Ernest TerribasiD, Marco A. FernándeziD, Gerard Requena, Inma RosasiD, Helena MazuelasiD, Itziar Uriarte-ArrazolaiD, Alejandro NegroiD, Elisabeth CastellanosiD, Ignacio BlancoiD, George H. DeVries, Hiroyuki KawashimaiD, Eric LegiusiD, Hilde BremsiD, Viktor F. Mautner, Lan KluweiD, Nancy RatneriD, Margaret Wallace, Juana Fernández Rodriguez, Conxi LázaroiD, Jonathan Alfred FletcheriD, David ReußiD, Meritxell CarrióiD, Bernat GeliD, Eduard SerraiD
Abstract
BackgroundMalignant peripheral nerve sheath tumors (MPNSTs) are soft tissue sarcomas that arise from the peripheral nervous system. Half of the tumors develop in the context of the genetic disease Neurofibromatosis type 1 (NF1) and the rest are sporadic sarcomas. MPNSTs have a dismal prognosis due to their aggressiveness and tendency to metastasize, and new treatment options are needed. The diagnosis of MPNSTs can be challenging, especially outside of the NF1 context since specific histological criteria have not been completely established. Genomic analysis may both facilitate differential diagnoses and suggest precision medicine strategies. MethodsWe generated a complete genomic resource of a set of widely used human NF1-related and sporadic MPNST cell lines by applying ploidy analysis, whole genome and whole exome sequencing and SNP-array analysis, complemented by methylome-based classification and immunofluorescence of cell identity markers (SOX9, SOX10, S100B). ResultsNF1 MPNST cell lines faithfully recapitulated the genomic copy number profile of primary MPNSTs. Structural variants were key players in the complete inactivation of most recurrently altered tumor suppressor genes (TSGs) (NF1, CDKN2A, SUZ12/EED), while small variants played a minor role in the NF1 context, both concerning TSG inactivation and due to the absence of gain-of-function mutations. In clear contrast, the sporadic cell lines (STS-26T, HS-Sch-2, HS-PSS) did not recapitulate the copy number profile of primary MPNSTs. They carried different TSG inactivation and exhibited gain-of-function mutations by predicted kinase activation or generation of fusion genes. Mutational frequencies and signatures emerged as promising informative tools for aiding in MPNST differential diagnosis. Due to the multiple genomic differences exhibited, we complemented their characterization using a methylome-based classifier. All NF1-related cell lines were assigned within the MPNST group, while sporadic cell lines clustered either with melanomas or with an uncertain MPNST-like sarcoma group. The staining of cell identity markers reinforced the idea of a potential misdiagnose of the MPNSTs used to derive the sporadic cell lines analyzed. ConclusionsDeep genomic analysis, together with methylome-based sarcoma classification and cell identity marker analysis, challenged the MPNST identity of sporadic cell lines. Results presented here open an opportunity to revise MPNST differential diagnosis and classification.
02 /Specification & Classification
Click any tag to browse matching papers- Citations
- 3
- Organism
- Assay
- Research Focus
- Approach
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Identification of Malignant Peripheral Nerve Sheath Tumor subtypes with distinct genomic identities
Miriam Magallón‐Lorenz, Juana Fernández‐Rodríguez, … Bernat Gel·bioRxiv·Apr 2, 2026
- Genomic patterns of malignant peripheral nerve sheath tumour (MPNST) evolution correlate with clinical outcome and are detectable in cell-free DNA
I. Cortes-Ciriano, C. D. Steele, … D. T. Miller·bioRxiv·May 3, 2022
- Genomic MET amplification occurs early in NF1-related malignant peripheral nerve sheath tumor (MPNST) progression and is a potent therapeutic target
Jacqueline D. Peacock, Matthew G. Pridgeon, … Matthew R. Steensma·bioRxiv·Oct 5, 2017
- Ex vivo to in vivo model of malignant peripheral nerve sheath tumors for precision oncology
H. Bhatia^, A. T. Larsson^, … A. C. Hirbe·bioRxiv·Apr 29, 2022
- A genetic mouse model with postnatal Nf1 and p53 loss recapitulates the histology and transcriptome of human malignant peripheral nerve sheath tumor
A. Inoue, L. J. Janke, … X. Cao·bioRxiv·May 3, 2021
- New cellular models of undifferentiated pleomorphic sarcoma and malignant peripheral nerve sheath tumor
A. D. Bhalla, S. M. Landers, … K. E. Torres·bioRxiv·May 13, 2021